Astrazenaca to buy Cambridge Antibody Technology (CAT)
Interesting news that Astrazenaca is to buy Cambridge Antibody Technology (CAT) for $1.3 billion. It will be interesting to see the fall out from this since CAT is working on a variety of projects for other pharma/biotech companies such as Genzyme. Here’s a list of CAT’s partners. Some of the larger players are Abbott, Human Genome Sciences, Merck, and Pfizer. Having been involved with a contract manufacturer who was bought by a competitor I can tell you there are some people who are scrambling to figure out a backup plan. There will definitely be some turmoil for a while but this may open the door to other antibody manufactures to possibly lure CAT’s partners away or at least be given serious consideration is a second source. It will be interesting to see how this develops.
Technorati Tags: astrazenaca
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
